Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$102.58 USD

102.58
1,970,294

+1.92 (1.91%)

Updated Aug 13, 2024 04:00 PM ET

Pre-Market: $108.08 +5.50 (5.36%) 9:06 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 21% (197 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain Stryker (SYK) Stock Right Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.

PerkinElmer's Non-Invasive Saliva-Based Testing Gets CE Mark

by Zacks Equity Research

PerkinElmer's (PKI) new saliva-based collection and asymptomatic test solution receives CE-IVD mark.

Why Cardinal Health (CAH) is Such a Great Value Stock Pick Right Now

by Zacks Equity Research

Cardinal Health (CAH) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.

Here's Why You Should Retain McKesson (MCK) Stock for Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.

CAH vs. ALGN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

CAH vs. ALGN: Which Stock Is the Better Value Option?

Has Cardinal Health (CAH) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (CAH) Outperforming Other Medical Stocks This Year?

Stock Market News for Nov 6, 2020

by Zacks Equity Research

U.S. stock markets closed sharply higher on Thursday as the wait for the U.S. Presidential election outcome continues.

Cardinal Health (CAH) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Cardinal Health's (CAH) fiscal first-quarter results reflect strong segmental performance.

Cardinal Health (CAH) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Cardinal (CAH) delivered earnings and revenue surprises of 32.46% and 1.68%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Cigna (CI) Maintain Its Beat Streak in Q3 Earnings?

by Zacks Equity Research

Cigna's (CI) Q3 results are likely to reflect revenue growth owing to a strong fundamental performance. Earnings, however, might have been affected by steep medical costs from moderation in deferment of care related to the COVID-19 pandemic.

Should You Buy Cardinal Health (CAH) Ahead of Earnings?

by Zacks Equity Research

Cardinal Health (CAH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Trina Mukherjee headshot

Medical Products' Nov 5 Earnings Roster: BDX, ABC & More

by Trina Mukherjee

Medical Product companies have shown strength in the third quarter on the back of huge adoption of COVID-19 related healthcare-support products and services despite the impact of the ongoing pandemic.

Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Cardinal Health's (CAH) fiscal first-quarter results are likely to reflect solid performance in Pharmaceutical segment.

DENTSPLY SIRONA (XRAY) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) third-quarter results are likely to reflect weak segmental performance.

AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.

Invitae (NVTA) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Invitae's (NVTA) genetic testing business is expected to have gained from expansion of biopharma partnerships in Q3.

Cardinal Health (CAH) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Trina Mukherjee headshot

3 Dental Supplies Stocks Set to Shine on the Industry's Upturn

by Trina Mukherjee

Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. CAH, WST and MCK are well positioned to gain from the prospects.

Henry Schein (HSIC) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Henry Schein's (HSIC) medical business' PPE sales are likely to have maintained its momentum along with global recovery trends of the dental business during Q3.

ABIOMED (ABMD) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

The full commercial launch of Impella 5.5 in May is expected to have contributed to ABIOMED's (ABMD) fiscal second-quarter results

Quidel (QDEL) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Quidel (QDEL) is likely to have witnessed an uptick in rapid immunoassay revenues in Q3.

DaVita (DVA) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Solid performance by the net dialysis and related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in the third quarter.

CAH vs. ALGN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

CAH vs. ALGN: Which Stock Is the Better Value Option?

What's in Store for IDEXX Laboratories (IDXX) in Q3 Earnings?

by Zacks Equity Research

IDEXX's (IDXX) third-quarter top line is likely to have benefited from strength in CAG and LPD businesses.

Illumina (ILMN) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Illumina (ILMN) is upbeat about its third-quarter sequencing consumable revenue growth.